Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?

Core Insights - Westshore Wealth, LLC has initiated a new position in Amneal Pharmaceuticals, acquiring 1,381,910 shares valued at approximately $13.83 million, representing 4.73% of its reportable equity portfolio as of September 30, 2025 [2][6] Company Overview - Amneal Pharmaceuticals has reported trailing twelve-month (TTM) revenue of $2.93 billion and net income of $5.90 million as of September 30, 2025 [3][4] - The company's stock price was $11.58 as of November 17, 2025, reflecting a 39.02% increase over the prior year [3][4] - Amneal's market capitalization stands at $3.64 billion [4] Financial Performance - Amneal's third quarter sales reached $784.5 million, up from $702.5 million in the prior year, contributing to a net income of $18.1 million compared to $11.8 million in 2024 [12] - The company has experienced year-over-year revenue growth for the last five years and projects sales of about $3 billion for 2025, an increase from $2.8 billion in 2024 [12] Investment Metrics - Amneal's forward P/E ratio is 12.29 and EV/EBITDA is 11.02 as of the latest filings [3] - The stock has an alpha of 16.51 percentage points compared to the S&P 500, indicating strong performance relative to the market [3] Product Portfolio - Amneal offers a broad portfolio of generic and specialty pharmaceutical products, including complex oral solids, injectables, and branded therapies for various medical conditions [8][9] - The company serves a diverse customer base, including wholesalers, distributors, hospitals, retail pharmacies, and U.S. government agencies, with a significant presence in both domestic and international markets [9][10]